In a brief filed with a federal district court in Delaware Friday (Jan. 26), the government stood its ground against claims by Novo Nordisk that CMS is imposing Medicare drug price negotiation on more drugs than Congress authorized in the Inflation Reduction Act (IRA). The brief comes as CMS is expected to submit its first offer of lower prices for 10 selected Part D drugs by Thursday (Feb. 1), and as nine active lawsuits remain in play challenging the new...